NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals (IONS) Stock Looks Fully Priced After FDA Rare Disease Approval
Ionis Pharmaceuticals stock has delivered a 51.6% gain over the past five years, yet current valuation checks flag the shares as screening on the expensive side rather than an obvious bargain. That mix of solid long term returns and a "mixed" value score puts the focus on what investors are now being asked to pay for the company’s drug portfolio and pipeline risk.
The 51.6% return over five years underlines that long term holders have been rewarded, which raises the bar for what future...